Galectin Therapeutics market cap GALT

Share price times shares outstanding: what the whole company sells for, since 2011.

Galectin Therapeutics is worth $321.7M at the close on Oct 23, 2026, at $3.19 a share.

That is down 4% over the last year and up 71% over five years.

Its highest close in our data was $464.9M in Sep 2026.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$321.7M	$138.2M	$464.9M	+23%
2025	$261.1M	$69M	$403M	+262%
2024	$72.2M	$65.3M	$245.8M	−30%
2023	$102.7M	$66M	$142.6M	+53%
2022	$67.2M	$67.2M	$134.2M	−45%
2021	$122.8M	$111.9M	$252.6M	−4%
2020	$127.9M	$98.1M	$179.6M	−22%
2019	$163.8M	$153.2M	$232.8M	+6%
2018	$155.1M	$123.6M	$330.2M	+30%
2017	$119M	$29.1M	$119M	+313%
2016	$28.8M	$17.9M	$79.9M	−27%
2015	$39.2M	$39.2M	$90.9M	−47%
2014	$73.7M	$73.7M	$344.8M	−50%
2013	$148M	$32.7M	$210.1M	+348%
2012	$33.1M	$26.7M	$75.5M	−55%
2011	$74M	$56.3M	$77.8M	n/a

Companies in Drug Manufacturers - General nearest Galectin Therapeutics' size, closest first, today.

Company	Market cap
GALTGalectin Therapeutics	$321.7M
ARVNArvinas	$477.3M
NATRNatures Sunshine Products	$213.8M
PBYIPuma Biotechnology	$568.9M
IRWDIronwood Pharmaceuticals	$571.7M
ZVRAZevra Therapeutics	$582.6M
CRMDCorMedix	$611.9M
COLLCollegium Pharmaceutical	$747.5M
ABUSArbutus Biopharma	$831M
AMPHAmphastar Pharmaceuticals	$1.1B
OMEROmeros	$1.2B
Peer median	$597.2M